Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

Gene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) showing strong associations with gene expression levels. We performed an association study to test whether eQTLs of genes reported to be associated with prognosis of MM patients are directly associated with measures of adverse outcome. Using the genotype‐tissue expression portal, we identified a total of 16 candidate genes with at least one eQTL SNP associated with their expression with P < 10−7 either in EBV‐transformed B‐lymphocytes or whole blood. We genotyped the resulting 22 SNPs in 1327 MM cases from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and examined their association with overall survival (OS) and progression‐free survival (PFS), adjusting for age, sex, country of origin and disease stage. Three polymorphisms in two genes (TBRG4‐rs1992292, TBRG4‐rs2287535 and ENTPD1‐rs2153913) showed associations with OS at P < .05, with the former two also associated with PFS. The associations of two polymorphisms in TBRG4 with OS were replicated in 1277 MM cases from the International Lymphoma Epidemiology (InterLymph) Consortium. A meta‐analysis of the data from IMMEnSE and InterLymph (2579 cases) showed that TBRG4‐rs1992292 is associated with OS (hazard ratio = 1.14, 95% confidence interval 1.04‐1.26, P = .007). In conclusion, we found biologically a plausible association between a SNP in TBRG4 and OS of MM patients.

[1]  H. Brenner,et al.  Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study , 2019, Leukemia & lymphoma.

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  D. Campa,et al.  Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients , 2018, British journal of haematology.

[4]  Junke Wang,et al.  gwasurvivr: an R package for genome wide survival analysis , 2018, bioRxiv.

[5]  Henrik Gréen,et al.  Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial , 2017, Cancer Chemotherapy and Pharmacology.

[6]  B. Weir,et al.  A genome-wide study of Hardy–Weinberg equilibrium with next generation sequence data , 2017, Human Genetics.

[7]  O. Stephens,et al.  A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3 , 2016, British journal of haematology.

[8]  H. Goldschmidt,et al.  A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis , 2016, Oncotarget.

[9]  Shane A. McCarthy,et al.  Reference-based phasing using the Haplotype Reference Consortium panel , 2016, Nature Genetics.

[10]  A. Vangsted,et al.  Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation , 2016, International journal of laboratory hematology.

[11]  Kenneth G. C. Smith,et al.  Insight into Genotype-Phenotype Associations through eQTL Mapping in Multiple Cell Types in Health and Immune-Mediated Disease , 2016, PLoS Genetics.

[12]  Manolis Kellis,et al.  HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease , 2015, Nucleic Acids Res..

[13]  D. Hose,et al.  Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells , 2015, BMC Medical Genomics.

[14]  G. Castellani,et al.  The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) , 2015, Oncotarget.

[15]  Nam-Kyung Yu,et al.  CTCF as a multifunctional protein in genome regulation and gene expression , 2015, Experimental & Molecular Medicine.

[16]  S. Ševčíková,et al.  Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. , 2015, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[17]  Caleb K. Stein,et al.  The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma , 2015, Leukemia.

[18]  Lude Franke,et al.  From genome to function by studying eQTLs. , 2014, Biochimica et biophysica acta.

[19]  J. Crowley,et al.  Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma , 2013, Leukemia.

[20]  Marcos González,et al.  Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma , 2013, British journal of haematology.

[21]  G. Requirand,et al.  Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors , 2013, British Journal of Cancer.

[22]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[23]  Y. Yasukochi,et al.  Current perspectives on the intensity of natural selection of MHC loci , 2013, Immunogenetics.

[24]  A. McKenna,et al.  Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci , 2013, Cell.

[25]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.

[26]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[27]  F. Vannberg,et al.  GENETICS OF GENE EXPRESSION IN PRIMARY IMMUNE CELLS IDENTIFIES CELL-SPECIFIC MASTER REGULATORS AND ROLES OF HLA ALLELES , 2012, Nature Genetics.

[28]  U. Vogel,et al.  Genetic variations in multiple myeloma II: association with effect of treatment , 2012, European journal of haematology.

[29]  V. Moreno,et al.  Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). , 2011, International journal of oncology.

[30]  B. Barlogie,et al.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma , 2011, International journal of hematology.

[31]  N. Cox,et al.  Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS , 2010, PLoS genetics.

[32]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Liang,et al.  A genome-wide association study of global gene expression , 2007, Nature Genetics.

[34]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[35]  Shaji K. Kumar,et al.  Multiple Myeloma: Diagnosis and Treatment. , 2005, Mayo Clinic proceedings.

[36]  M. Urashima,et al.  Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. , 1996, Blood.

[37]  Toshio Matsumoto,et al.  TGF-β-related mechanisms of bone destruction in multiple myeloma. , 2011, Bone.

[38]  H. Goldschmidt,et al.  Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma , 2022 .

[39]  Jennifer L. Caswell-Jin,et al.  Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients , 2022 .